MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study

PURPOSE: Addition of bevacizumab to trastuzumab-based neoadjuvant chemotherapy in HER2-positive inflammatory breast cancer (IBC) was associated with favorable outcome in the BEVERLY-2 phase II trial. Circulating levels of matrix metalloproteinases (MMP) 2 and 9 were correlated to high response rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabouret, Emeline, Bertucci, François, Pierga, Jean-Yves, Petit, Thierry, Levy, Christelle, Ferrero, Jean-Marc, Campone, Mario, Gligorov, Joseph, Lerebours, Florence, Roché, Henri, Bachelot, Thomas, van Laere, Steven, Ueno, Naoto T., Toiron, Yves, Finetti, Pascal, Birnbaum, Daniel, Borg, Jean-Paul, Viens, Patrice, Chinot, Olivier, Gonçalves, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951307/
https://www.ncbi.nlm.nih.gov/pubmed/26921265
http://dx.doi.org/10.18632/oncotarget.7612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951307/
https://www.ncbi.nlm.nih.gov/pubmed/26921265
http://dx.doi.org/10.18632/oncotarget.7612

Ejemplares similares